Kodiak Sciences: HC Wainwright Raises PT to $5, Maintains Neutral Rating

Kodiak Sciences: HC Wainwright Raises PT to $5, Maintains Neutral Rating

July 2, 2025

Financial analysts at HC Wainwright have upgraded their price target for Kodiak Sciences Inc. (NASDAQ: KOD) to $5.00, while maintaining a Neutral rating on the stock. This move comes amidst a challenging year for the biopharmaceutical company, which has seen its stock price tumble to a 52-week low at $2.15 [1].

Kodiak Sciences Inc. is a clinical-stage biopharmaceutical company that focuses on the research, development, and commercialization of therapeutics for retinal diseases. Its lead product candidate, tarcocimab tedromer (KSI-301), is an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has completed Phase 3 clinical studies for high prevalence retinal vascular diseases and is in Phase 3 for diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 for wet AMD [2].

The upgrade in the price target by HC Wainwright follows a series of recent analyst updates. JPMorgan recently upgraded Kodiak Sciences Inc. from Underweight to Neutral and established a price target of $9.40 [3]. Additionally, the company has been actively presenting its data and business highlights at various industry conferences, including the ARVO 2025 conference, where it highlighted the power and versatility of its ABC platform in addressing complex multifactorial ocular diseases [4].

Despite the positive analyst sentiment, Kodiak Sciences Inc. has been facing financial challenges. The company reported a net income loss of $199.825 for the first quarter of 2025, with an EPS of -$3.79 [5]. The company has also been experiencing rapid cash burn, which could impact its financial stability in the short term.

The Neutral rating from HC Wainwright suggests that while there is potential in the company's pipeline, the current market conditions and financial performance pose risks. Investors should closely monitor the company's financial results and clinical trial data to make informed investment decisions.

References:

[1] Investing.com. (Apr 04, 2025). Kodiak Sciences stock hits 52-week low at $2.15. Retrieved from [https://www.investing.com/equities/kodiak-sciences-inc](https://www.investing.com/equities/kodiak-sciences-inc).

[2] Kodiak Sciences Inc. (May 01, 2025). Kodiak Sciences Data at ARVO 2025 Highlight Power and Versatility of ABC Platform in Addressing Complex Multifactorial Ocular Diseases. Retrieved from [https://www.investing.com/equities/kodiak-sciences-inc](https://www.investing.com/equities/kodiak-sciences-inc).

[3] Investing.com. (Aug 14, 2025). JPMorgan upgrades Kodiak Sciences stock rating to Neutral from Underweight. Retrieved from [https://www.investing.com/equities/kodiak-sciences-inc](https://www.investing.com/equities/kodiak-sciences-inc).

[4] Kodiak Sciences Inc. (Jun 25, 2025). Kodiak Sciences to Present KSI-101 Highlights at 2025 Congress of the International Ocular Inflammation Society. Retrieved from [https://www.investing.com/equities/kodiak-sciences-inc](https://www.investing.com/equities/kodiak-sciences-inc).

[5] Kodiak Sciences Inc. (May 14, 2025). Kodiak Sciences Announces Recent Business Highlights and First Quarter 2025 Financial Results. Retrieved from [https://www.investing.com/equities/kodiak-sciences-inc](https://www.investing.com/equities/kodiak-sciences-inc).